Pfizer outlines post-merger leadership team

US pharma giant Pfizer (NYSE: PFE) has named the executive leadership team that will take up the reins after its acquisition of Irish-based Allergan (NYSE: AGN) is finalised at the end of this year.

Viagra maker Pfizer agreed at the end of November 2015 to acquire Botox manufacturer Allergan for $160 billion in a controversial tax inversion deal.

In a statement published yesterday (February 8), the drugmaker said it will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction.